145 related articles for article (PubMed ID: 22101219)
1. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer.
Kumar N; Crocker T; Smith T; Pow-Sang J; Spiess PE; Egan K; Quinn G; Schell M; Sebti S; Kazi A; Chuang T; Salup R; Helal M; Zagaja G; Trabulsi E; McLarty J; Fazili T; Williams CR; Schreiber F; Slaton J; Anderson JK
Contemp Clin Trials; 2012 Mar; 33(2):279-85. PubMed ID: 22101219
[TBL] [Abstract][Full Text] [Related]
2. Challenges to Recruiting Men on Active Surveillance for Prostate Cancer in Clinical Chemoprevention Trials.
Kumar NB; Bahl S; Dhillon J; Poch M; Manley B; Li R; Schell M; Powsang J
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831597
[TBL] [Abstract][Full Text] [Related]
3. Recruitment strategies for a lung cancer chemoprevention trial involving ex-smokers.
Kye SH; Tashkin DP; Roth MD; Adams B; Nie WX; Mao JT
Contemp Clin Trials; 2009 Sep; 30(5):464-72. PubMed ID: 19508900
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial.
Loehberg CR; Jud SM; Haeberle L; Heusinger K; Dilbat G; Hein A; Rauh C; Dall P; Rix N; Heinrich S; Buchholz S; Lex B; Reichler B; Adamietz B; Schulz-Wendtland R; Beckmann MW; Fasching PA
Breast Cancer Res Treat; 2010 May; 121(1):101-10. PubMed ID: 20306293
[TBL] [Abstract][Full Text] [Related]
5. Accrual issues for chemoprevention trials: the example of the 4-HPR study for the prevention of contralateral breast cancer.
Camerini T; De Palo G; Mariani L; Marubini E; Costa A; Veronesi U
Tumori; 1999; 85(4):299-303. PubMed ID: 10587038
[TBL] [Abstract][Full Text] [Related]
6. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?
Gontero P; Marra G; Soria F; Oderda M; Zitella A; Baratta F; Chiorino G; Gregnanin I; Daniele L; Cattel L; Frea B; Brusa P
Prostate; 2015 Aug; 75(11):1177-86. PubMed ID: 25893930
[TBL] [Abstract][Full Text] [Related]
7. Designing a randomized phase I/II prostate cancer chemoprevention trial using 1alpha-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D3.
Packianathan S; Mehta RG; Mehta RR; Hall WH; Boerner PS; Beckett LA; Vijayakumar S
Cancer J; 2004; 10(6):357-67. PubMed ID: 15701267
[TBL] [Abstract][Full Text] [Related]
8. Implementing a Memory Clinic Model to Facilitate Recruitment into Early Phase Clinical Trials for Mild Cognitive Impairment and Alzheimer's Disease.
Park L; Kouhanim C; Lee S; Mendoza Z; Patrick K; Gertsik L; Aguilar C; Gullaba D; Semenova S; Jhee S
J Prev Alzheimers Dis; 2019; 6(2):135-138. PubMed ID: 30756120
[TBL] [Abstract][Full Text] [Related]
9. Moving a randomized clinical trial into an observational cohort.
Goodman PJ; Hartline JA; Tangen CM; Crowley JJ; Minasian LM; Klein EA; Cook ED; Darke AK; Arnold KB; Anderson K; Yee M; Meyskens FL; Baker LH
Clin Trials; 2013 Feb; 10(1):131-42. PubMed ID: 23064404
[TBL] [Abstract][Full Text] [Related]
10. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.
Lucia MS; Darke AK; Goodman PJ; La Rosa FG; Parnes HL; Ford LG; Coltman CA; Thompson IM
Cancer Prev Res (Phila); 2008 Aug; 1(3):167-73. PubMed ID: 19138952
[TBL] [Abstract][Full Text] [Related]
11. Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial.
Dew A; Khan S; Babinski C; Michel N; Heffernan M; Stephan S; Jordan N; Jovanovic B; Carney P; Bergan R
Clin Trials; 2013 Apr; 10(2):292-9. PubMed ID: 23321266
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R;
J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831
[TBL] [Abstract][Full Text] [Related]
13. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.
Taneja SS; Morton R; Barnette G; Sieber P; Hancock ML; Steiner M
J Clin Oncol; 2013 Feb; 31(5):523-9. PubMed ID: 23295793
[TBL] [Abstract][Full Text] [Related]
15. Minority recruitment in the prostate cancer prevention trial.
Moinpour CM; Atkinson JO; Thomas SM; Underwood SM; Harvey C; Parzuchowski J; Lovato LC; Ryan AM; Hill MS; Deantoni E; Gritz ER; Thompson IM; Coltman CA
Ann Epidemiol; 2000 Nov; 10(8 Suppl):S85-91. PubMed ID: 11189097
[TBL] [Abstract][Full Text] [Related]
16. A review of phase III clinical trials of prostate cancer chemoprevention.
Thorpe JF; Jain S; Marczylo TH; Gescher AJ; Steward WP; Mellon JK
Ann R Coll Surg Engl; 2007 Apr; 89(3):207-11. PubMed ID: 17394699
[TBL] [Abstract][Full Text] [Related]
17. The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial.
Lewis R; Todd R; Newton M; Jones RJ; Wilson C; Donovan JL; Bryan RT; Birtle A; Hall E;
Trials; 2020 Jul; 21(1):629. PubMed ID: 32641097
[TBL] [Abstract][Full Text] [Related]
18. Statistical considerations of chemoprevention clinical trials in prostate cancer.
Sylvester R; Collette L
Eur Urol; 1999; 35(5-6):519-22. PubMed ID: 10325518
[TBL] [Abstract][Full Text] [Related]
19. A web-based screening and accrual strategy for a cancer prevention clinical trial in healthy smokers.
Mohebati A; Knutson A; Zhou XK; Smith JJ; Brown PH; Dannenberg AJ; Szabo E
Contemp Clin Trials; 2012 Sep; 33(5):942-8. PubMed ID: 22771576
[TBL] [Abstract][Full Text] [Related]
20. Costs of recruiting couples to a clinical trial.
Sadler GR; Ko CM; Malcarne VL; Banthia R; Gutierrez I; Varni JW
Contemp Clin Trials; 2007 Jul; 28(4):423-32. PubMed ID: 17218166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
